Compugen Showcases COM503 Results at SITC, Advancing Cancer Immunotherapy Efforts

Compugen Advances Cancer Immunotherapy with COM503 Presentation

Compugen Ltd., a clinical-stage cancer immunotherapy company based in Holon, Israel, reaches a significant milestone with its first human trial results for the anti-IL18BP antibody, COM503 (GS-0321). The findings are set to be presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 7, 2025. The presentation will be made by Dr. Manish Sharma, MD, Co-Director of Clinical Research at START Midwest, highlighting the innovative approaches Compugen is employing in the fight against advanced solid tumors. This trial represents a critical step in evaluating the safety and efficacy of COM503, as the company seeks to establish its foothold in the competitive landscape of cancer immunotherapy.

The anti-IL18BP antibody COM503 is part of Compugen’s broader strategy to leverage its AI/ML-driven computational platform, Unigen™, for drug discovery. By identifying new therapeutic targets, Compugen aims to develop treatments that enhance the body’s immune response against cancer. The ongoing Phase 1 trial of COM503 is particularly noteworthy as it explores a novel mechanism of action that could potentially improve patient outcomes in advanced malignancies. The presentation at SITC is anticipated to provide valuable insights into the antibody's performance, offering a glimpse into the future of immuno-oncology.

In addition to COM503, Compugen boasts a robust pipeline that includes two other proprietary candidates, COM701 and COM902, both of which target PVRIG and TIGIT, respectively, and are also in Phase 1 development. Furthermore, the company has partnered with AstraZeneca for the development of Rilvegostomig, a PD-1/TIGIT bispecific antibody that is currently in Phase 3 trials. This strategic collaboration underscores Compugen’s commitment to advancing cancer immunotherapy and highlights its potential to bring innovative treatments to market.

Compugen continues to strengthen its presence in the immunotherapy sector, operating from both Holon and San Francisco. The company’s focus on novel mechanisms to enhance immune responses against cancer places it at the forefront of cancer research, with promising developments that could significantly impact treatment paradigms. With the upcoming presentation of COM503, Compugen is poised to capture attention within the immuno-oncology community, showcasing its dedication to pioneering advancements in cancer therapies.